Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | KDR | P35968 | 6/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | CLK1 | P49759 | 3/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062035 | 0.92 | ABL1 (0.46) | ABL1AXLSRCMAPTNPC1 | |
| SCHEMBL5062357 | 0.91 | MAPK14 (0.47) | ABL1AXLSRCBRAFKDR | |
| SCHEMBL5056510 | 0.90 | ABL1 (0.44) | ABL1AXLSRCMAPTNPC1 | |
| SCHEMBL5052156 | 0.89 | ABL1 (0.44) | ABL1AXLSRCBRAFKDR | |
| SCHEMBL5052136 | 0.87 | RAF1 (0.51) | ABL1AXLSRCMEN1KMT2A | |
| SCHEMBL5055058 | 0.87 | IMPDH2 (0.40) | BRAFKDRMAPK14RAF1TNNI3K | |
| SCHEMBL5054508 | 0.85 | KDR (0.37) | BRAFKDRMAPK14RAF1TNNI3K | |
| SCHEMBL5056313 | 0.85 | FDPS (0.40) | SRCNPC1MEN1KMT2ABRAF | |
| SCHEMBL5052271 | 0.84 | KDR (0.52) | ABL1AXLSRCKDRPDGFRA | |
| SCHEMBL5054888 | 0.84 | KDR (0.44) | ABL1AXLSRCKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ABL1 20/4885AXL 117/4885SRC 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.